echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Silitan, a new antihypertensive drug of xinlitai, plans to carry out overseas registration and clinical work

    Silitan, a new antihypertensive drug of xinlitai, plans to carry out overseas registration and clinical work

    • Last Update: 2020-04-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Xinlitai (Ye Yuxiang, general manager, said at the performance briefing today that the company's new product, xinlitan (alisartan ester tablets), is a global innovative product

    At present, it has obtained or applied for patent authorization in Europe, the United States and other countries, and the company is now selecting appropriate countries to carry out overseas registration and clinical work of xinlitan

    Ye Yuxiang said that xinlitan is a rare class 1.1 new anti hypertension drug independently developed in China

    The patent protection period is until 2026, the product has low toxicity, the consistency of antihypertensive effect is better than that of similar products, and it is suitable for long-term use

    At present, the population of hypertension in China reaches 200 million, and the market prospect is very large

    Xinlitan is an innovative drug purchased by xinlitai with a capital of 340 million yuan

    It obtained the production approval document at the end of October last year and has been put on the market for sale

    Ye Yuxiang once predicted that if xinlitan could enter the national medical insurance catalog or provincial medical insurance catalog and use the existing hospital channels of the company's products, the future sales revenue would reach 3 billion

    Xinlitai is mainly engaged in cardiovascular and cerebrovascular preparations, and its main products "Taijia" (clopidogrel tablets) and "xindayi" (benazepril hydrochloride tablets) have passed the EU certification and obtained the marketing license of European multi-national markets

    In 2013, xinlitai began to sell in the EU market.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.